Innovative radioisotope therapy for patients with neuroendocrine tumors using an alpha (<sup>225</sup>Ac) emitter labeled somatostatin analog: octreotate. A promising new treatment for advanced, progressive neuroendocrine neoplasms
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.